1. Home
  2. COLL vs CMCO Comparison

COLL vs CMCO Comparison

Compare COLL & CMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • CMCO
  • Stock Information
  • Founded
  • COLL 2002
  • CMCO 1875
  • Country
  • COLL United States
  • CMCO United States
  • Employees
  • COLL N/A
  • CMCO N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • CMCO Construction/Ag Equipment/Trucks
  • Sector
  • COLL Health Care
  • CMCO Industrials
  • Exchange
  • COLL Nasdaq
  • CMCO Nasdaq
  • Market Cap
  • COLL 1.1B
  • CMCO 1.1B
  • IPO Year
  • COLL 2015
  • CMCO 1996
  • Fundamental
  • Price
  • COLL $31.09
  • CMCO $39.02
  • Analyst Decision
  • COLL Strong Buy
  • CMCO Strong Buy
  • Analyst Count
  • COLL 6
  • CMCO 2
  • Target Price
  • COLL $42.00
  • CMCO $51.50
  • AVG Volume (30 Days)
  • COLL 439.3K
  • CMCO 221.2K
  • Earning Date
  • COLL 11-07-2024
  • CMCO 01-29-2025
  • Dividend Yield
  • COLL N/A
  • CMCO 0.73%
  • EPS Growth
  • COLL 757.11
  • CMCO N/A
  • EPS
  • COLL 2.16
  • CMCO 0.52
  • Revenue
  • COLL $599,245,000.00
  • CMCO $1,001,648,000.00
  • Revenue This Year
  • COLL $13.20
  • CMCO $1.62
  • Revenue Next Year
  • COLL $17.63
  • CMCO $5.44
  • P/E Ratio
  • COLL $14.32
  • CMCO $73.40
  • Revenue Growth
  • COLL 9.62
  • CMCO 2.41
  • 52 Week Low
  • COLL $28.97
  • CMCO $29.26
  • 52 Week High
  • COLL $42.29
  • CMCO $45.84
  • Technical
  • Relative Strength Index (RSI)
  • COLL 48.70
  • CMCO 51.84
  • Support Level
  • COLL $29.67
  • CMCO $39.63
  • Resistance Level
  • COLL $31.10
  • CMCO $39.26
  • Average True Range (ATR)
  • COLL 0.98
  • CMCO 0.81
  • MACD
  • COLL 0.26
  • CMCO -0.28
  • Stochastic Oscillator
  • COLL 69.41
  • CMCO 8.47

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, Middle East, and Africa.

Share on Social Networks: